Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

AbbVie Drug Filing Is Enanta Windfall

by Lisa M. Jarvis
April 28, 2014 | A version of this story appeared in Volume 92, Issue 17

Enanta Pharmaceuticals received a $20 million payment from AbbVie after AbbVie filed for FDA approval for an all-oral regimen that treats the hepatitis C virus. The drug includes the NS5A inhibitor ABT-267, the nonnucleoside polymerase inhibitor ABT-333, and the boosted protease inhibitor ABT-450/ritonavir, which was developed in collaboration with Enanta. The Watertown, Mass.-based biotech firm stands to receive another $20 million in May, when AbbVie expects to file for approval in Europe.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.